Skip to content

Erasca, Inc. ERAS Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Eli Lilly logo
Eli LillyLLY
1.4×-1.1×
Pfizer logo
PfizerPFE
0.7×0.0×
Amgen logo
AmgenAMGN
6.2×-3.0×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
0.1×0.0×
Tango Therapeutics logo
Tango TherapeuticsTNGX
0.1×-0.1×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s debt-to-equity?
Erasca, Inc. (ERAS) reported debt-to-equity of 0.1× in Q1 2026.
How has Erasca, Inc.'s debt-to-equity changed year-over-year?
Erasca, Inc.'s debt-to-equity decreased by 8.2% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Erasca, Inc.'s debt-to-equity?
Over 4 years (2021 to 2025), Erasca, Inc.'s debt-to-equity has grown at a 37.0% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.